Genomic analysis of immune cell infiltrates across 11 tumor types

Journal of the National Cancer Institute

Volumn 108, Issue 11, 2016, Pages

  Iglesia, Michael D ^a   Parker, Joel S ^a   Hoadley, Katherine A ^a,b   Serody, Jonathan S ^a,b   Perou, Charles M ^a,b   Vincent, Benjamin G ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; MESSENGER RNA; CELL SURFACE RECEPTOR;

ARTICLE; B LYMPHOCYTE; BREAST CANCER; BREAST TUMOR; CANCER SURVIVAL; CELL INFILTRATION; ENDOMETRIUM TUMOR; GENE EXPRESSION; GENOMICS; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; LUNG TUMOR; MELANOMA; NEOPLASM; OVERALL SURVIVAL; PRIORITY JOURNAL; RNA SEQUENCE; GENETICS; IMMUNOLOGY; MACROPHAGE; PROGNOSIS; SURVIVAL RATE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

B-LYMPHOCYTES; GENE EXPRESSION; GENOMICS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; NEOPLASMS; PROGNOSIS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85014834973     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw144     Document Type: Article

References (56)

1. Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg. 1990; 125(2): 200-205.
2. Lee S, Margolin K. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep. 2012; 14(5): 468-474.
3. Kandalaft LE, Motz GT, Duraiswamy J, et al. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev. 2011; 30(1): 141-151.
4. Anagnostou VK, Brahmer JR. Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer. Clin Cancer Res. 2015; 21(5): 976-984.
5. Finke JH, Rayman PA, Ko JS, et al. Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Cancer J. 2013; 19(4): 353-364.
6. Liakou CI, Narayanan S, Ng Tang D, et al. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun. 2007; 7: 10.
7. Schoenfeld JD. Immunity in head and neck cancer. Cancer Immunol Res. 2015; 3(1): 12-17.
8. Lee AH, Gillett CE, Ryder K, et al. Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology. 2006; 48(6): 692-701.
9. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigenspecific CD8 T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002; 99(25): 16168-16173.
10. Milne K, Kobel M, Kalloger SE, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009; 4(7): e6412.
11. Galon J, Pages F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012; 10: 205.
12. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4): 782-795.
13. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024): 1565-1570.
14. Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009; 69(5): 2000-2009.
15. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013; 35(5): 585-600.
16. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009; 182(8): 4499-4506.
17. Hoadley KA, Yau C, Wolf DM, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014; 158(4): 929-944.
18. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155(2): 462-477.
19. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008; 105(8): 3005-3010.
20. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528): 563-567.
21. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26): 2443-2454.
22. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003; 100(14): 8372-8377.
23. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528): 558-562.
24. Kluger H, Sznol M, Callahan M, et al. Survival, Response Duration, and Activity by Braf Mutation (Mt) Status in a Phase 1 Trial of Nivolumab (Anti-Pd-1, Bms-936558, Ono-4538) and Ipilimumab (Ipi) Concurrent Therapy in Advanced Melanoma (Mel). Ann Oncol. 2014; 25.
25. Robert L, Tsoi J, Wang X, et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014; 20(9): 2424-2432.
26. Cancer Genome Atlas Network. Electronic address imo, Cancer Genome Atlas N. Genomic Classification of Cutaneous Melanoma. Cell. 2015; 161(7): 1681-1696.
27. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489(7417): 519-525.
28. Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014; 111(8): 3110-3115.
29. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418): 61-70.
30. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407): 330-337.
31. Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536): 576-582.
32. Brooks SA, Brannon AR, Parker JS, et al. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol. 2014; 66(1): 77-84.
33. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511): 543-550.
34. Ojala KA, Kilpinen SK, Kallioniemi OP. Classification of unknown primary tumors with a data-driven method based on a large microarray reference database. Genome Med. 2011; 3(9): 63.
35. Iglesia MD, Vincent BG, Parker JS, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res. 2014; 20(14): 3818-3829.
36. Fan C, Prat A, Parker JS, et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics. 2011; 4: 3.
37. Palmer C, Diehn M, Alizadeh AA, et al. Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics. 2006; 7: 115.
38. Schmidt M, Bohm D, von Torne C, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008; 68(13): 5405-5413.
39. Rody A, Karn T, Liedtke C, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011; 13(5): R97.
40. Rody A, Holtrich U, Pusztai L, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009; 11(2): R15.
41. Beck AH, Espinosa I, Edris B, et al. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res. 2009; 15(3): 778-787.
42. Team RDC. R: A Language and Environment for Statistical Computing. In; 2011.
43. Therneau T. A Package for Survival Analysis in S. In; 2012.
44. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A. 2001; 98(22): 12659-12664.
45. Coronella JA, Spier C, Welch M, et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol. 2002; 169(4): 1829-1836.
46. Sainz-Perez A, Lim A, Lemercier B, et al. The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res. 2012; 72(14): 3557-3569.
47. Buchbinder EI, McDermott DF. Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma. Clin Ther. 2015; 37(4): 755-763.
48. Massari F, Santoni M, Ciccarese C, et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev. 2015; 41(2): 114-121.
49. Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8 lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29(15): 1949-1955.
50. Mahmoud SM, Lee AH, Paish EC, et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012; 132(2): 545-553.
51. Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011; 71(4): 1263-1271.
52. Dalerba P, Maccalli C, Casati C, et al. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol. 2003; 46(1): 33-57.
53. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353(25): 2654-2666.
54. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26): 2509-2520.
55. Hitchcock ER, Morris CS. Mononuclear cell infiltration in central portions of human astrocytomas. J Neurosurg. 1988; 68(3): 432-437.
56. Morantz RA, Wood GW, Foster M, et al. Macrophages in experimental and human brain tumors. Part 1: Studies of the macrophage content of experimental rat brain tumors of varying immunogenicity. J Neurosurg. 1979; 50(3): 298-304.